U.S., July 15 -- ClinicalTrials.gov registry received information related to the study (NCT07062627) titled 'Anbalcabtagene Autoleucel in Relapsed/Refractory CNS Lymphoma' on May 27.
Brief Summary: This clinical study aims to evaluate the tolerability, safety, and efficacy of Anbal-cel in patients with recurrent or refractory PCNSL or SCNSL.
Subjects who have provided written consent and meet the inclusion and exclusion criteria through screening evaluations will undergo leukapheresis (LP) for Anbal-cel manufacturing. Subjects whose collected nucleated cells are confirmed suitable for Anbal-cel production will be enrolled in the clinical study.
Prior to Anbal-cel administration, lymphodepletion therapy will be performed and must be compl...